Dale Schaar is an Oncology physician affiliated with Rutgers. OpenAlex indexes 46 publications with 1,076 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
195 Little Albany St
New Brunswick, NJ 089011914
Telephone
732-235-2465Provider last certified this registry record 9 Apr 2024.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20221 payment
- Novartis Pharmaceuticals CorporationProgram year20221 payment
- E.R. Squibb & Sons, L.L.C.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor83.8%Tasigna30%Gleevec27%Sprycel25%Imatinib Mesylate18%Part D<11 patientsBCL-2 Inhibitor16.2%Venclexta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2009–2011 per NIH RePORTER. The latest:
- The Role of MicroRNAs in Human Hematopoietic Cell Differentiation
Univ of Med/dent Nj-R W Johnson Med Sch
FY2011$137,160K08HL092033 - The Role of MicroRNAs in Human Hematopoietic Cell Differentiation
Univ of Med/dent Nj-R W Johnson Med Sch
FY2010$137,160K08HL092033 - The Role of MicroRNAs in Human Hematopoietic Cell Differentiation
Univ of Med/dent Nj-R W Johnson Med Sch
FY2009$137,160K08HL092033
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
Cancer Chemotherapy and Pharmacology
2025 - Prophylactic Vancomycin in the Primary Prevention of <i>Clostridium difficile</i> in Allogeneic Stem Cell Transplant
Transplant Infectious Disease
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Sherine Gabriel, MD
Rutgers
Julius Gardin, MD
Rutgers
Abraham Aviv, MD
Rutgers
Partho Sengupta, MD, DM
Rutgers
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”